Kaleido Biosciences, Inc.
KLDO · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | 0.14 | -0.03 | -0.10 |
| FCF Yield | -78.19% | -21.53% | -61.52% | -11.79% |
| EV / EBITDA | -0.98 | -3.63 | -0.90 | -6.05 |
| Quality | ||||
| ROIC | -239.53% | -164.95% | -120.37% | -81.80% |
| Gross Margin | -113.59% | -5,640.21% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 0.75 | 0.88 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -19.35% | 17.43% | -60.96% | -106.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | 0.33 | 0.59 | 1.04 |
| Interest Coverage | -30.89 | -28.15 | -88.70 | -60.38 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -877.67 | -35,145.44 | -558.30 | 0.00 |